Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 14, Issue 7, 1996, Pages 2160-2166

  Juliusson, G ^a   Christiansen, I ^a   Hansen, M M ^a   Johnson, S ^a   Kimby, E ^a   Elmhorn Rosenborg, A ^a   Liliemark, J ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE;

ADULT; ARTICLE; B CELL LEUKEMIA; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SCREENING; FEMALE; HEMOLYSIS; HUMAN; INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029956950     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.7.2160     Document Type: Article

References (29)

1. J. Keating MJ, O'Brien S, Kantarjian H, et al: Long-term followup of patients with chronic lymphocytic leukemia treated with fludarabine as single agent. Blood 81:2878-2884, 1993
2. Pott-Hoeck C, Hiddeman W: Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias. Ann Oncol 6:421-433, 1995
3. Juliusson G, Liliemark J: High complete remission rate from 2-chloro-2′-deoxyadenosine (CdA) in previously treated patients with B-cell chronic lymphocytic leukemia: Response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 11:679-689, 1993
4. Saven A, Lemon RH, Kosty M, Beutler E, Piro LD: 2-Chloro-deoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 13:570-574, 1995
5. Delannoy A, Martial P, Gala JL, et al: 2-Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL). Leukemia 9:1130-1135, 1995
6. Kay AC, Saven A, Carrera CJ, et al: 2-Chlorodeoxyadenosine treatment of low-grade lymphoma. J Clin Oncol 10:371-377, 1992
7. O'Brien S, Kurzrock R, Duvic M, et al: 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood 84:733-738, 1994
8. Dimopoulos MA, O'Brien S, Kantarjian H, et al: Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues. Leuk Lymph 11:105-108, 1993, (suppl 2)
9. Gandhi V, Estey E, Keating MJ, et al: Fludarabine potentiates metabolism of cytarabine in patients with acute myelogeneous leukemia during therapy. J Clin Oncol 11:116-124, 1993
10. Santana VM, Hurwitz CA, Blakley RL, et al: Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 1994; 84:1237-1242
11. Juliusson G, Liliemark J: 2-Chlorodeoxyadenosine with and without cytosin arabinoside and idarubicin for acute myeloid and lymphoid leukemia-Clinical and pharmacokinetic studies. Br J Haematol 87:12, 1994 (suppl 1, abstr 48)
12. Beutler E: Cladribine (2-chlorodeoxyadenosine). Lancet 340:952-956, 1992
13. Juliusson G, Heldal D, Hippe E, et al: Subcutaneous injection of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 13:989-995, 1995
14. Juliusson G, Lenkei R, Liliemark J: Flow cytometry of blood and bone marrow cells in hairy cell leukemia. Phenotype of hairy cells and lymphocyte subsets following treatment with 2-chlorodeoxyadenosine. Blood 83:3672-3681, 1994
15. Juliusson G: Immunologic and genetic abnormalities in chronic lymphocytic leukaemia. Drugs 47:19-29, 1994, (suppl 6)
16. Sipe JC, Romine JS, Koziol JA, et al: Cladribine in the treatment of chronic progressive multiple sclerosis. Lancet 344:9-13, 1994
17. Oberhuber G, Schmid T, Thaler W, et al: Evidence that 2-chlorodeoxyadenosine in combination with cyclosporine prevents rejection after allogeneic small bowel transplantation. Transplantation 58:743-745, 1994
18. Liliemark J, Juliusson G: On the pharmacokinetics of 2-chloro-2′-deoxy-adenosine in humans. Cancer Res 51:5570-5572, 1991
19. Liliemark J, Juliusson G: Cellular pharmacokinetics of 2-chloro-2′-deoxyadenosine nucleotides: Comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin Cancer Res 1:385-390, 1995
20. Kemena A, Keating MJ, Plunckett W: Bioavailability of plasma fludarabine and fludarabine triphosphate (F-ara-ATP) in circulating CLL cells. Blood 76:288a, 1990 (suppl 1, abstr 1142)
21. Liliemark J, Albertioni F, Hassan M, et al: Bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: Alternative routes of administration. J Clin Oncol 10:1514-1518, 1992
22. Juliusson G, Liliemark J: Complete remission of B-cell chronic lymphocytic leukaemia after oral cladribine. Lancet 341:54, 1993 (letter)
23. Rai KR, Sawitsky A, Cronkite EP, et al: Clinical staging of chronic lymphocytic leukemia. Blood 46:219-234, 1975
24. Kazimierczuk Z, Cottam HB, Ravankar GR, et al: Synthesis of 2′-deoxytubericin, 2′-deoxyadenosin and related 2′-deoxynucleosides via a novel direct stereospecific serum salt glycosylation procedure. J Am Chem Soc 106:6379-6382, 1984
25. Cheson BD, Bennett JM, Rai KR, et al: Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored Working Group. Am J Hematol 29:152-163, 1988
26. Binet JL, Auquier A, Dighiero G, et al: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198-206, 1981
27. Keating M, Lerner S, O'Brien S, et al: Long-term follow-up of patients with chronic lymphocytic leukemia receiving fludarabine regimens as initial therapy. Proc Am Soc Clin Oncol 14:337, 1995 (abstr 1012)
28. Albertioni F, Pettersson B, Reichelová V, et al: Analysis of 2-chloro-2′-deoxyadenosine in human blood plasma and urine by high-performance liquid chromatography using solid-phase extraction. Ther Drug Monit 16:413-418, 1994
29. Juliusson G, Lenkei R, Tjønnfjord G, et al: Low-dose cladribine for symptomatic hairy cell leukaemia. Br J Haematol 89:637-639, 1995